Incyte INCY has been analyzed by 15 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 2 | 1 | 11 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 2 | 0 | 0 |
| 2M Ago | 2 | 1 | 7 | 1 | 0 |
| 3M Ago | 0 | 0 | 1 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Incyte, presenting an average target of $73.27, a high estimate of $97.00, and a low estimate of $52.00. This current average reflects an increase of 7.53% from the previous average price target of $68.14.
Deciphering Analyst Ratings: An In-Depth Analysis
A comprehensive examination of how financial experts perceive Incyte is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Derek Archila | Wells Fargo | Raises | Equal-Weight | $70.00 | $68.00 |
| Nicholas Holowko | UBS | Announces | Neutral | $77.00 | - |
| Brian Abrahams | RBC Capital | Lowers | Sector Perform | $74.00 | $80.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $80.00 | $72.00 |
| Derek Archila | Wells Fargo | Raises | Equal-Weight | $68.00 | $62.00 |
| David Lebowitz | Citigroup | Raises | Buy | $97.00 | $92.00 |
| Vikram Purohit | Morgan Stanley | Raises | Equal-Weight | $69.00 | $64.00 |
| Salveen Richter | Goldman Sachs | Raises | Neutral | $70.00 | $63.00 |
| Brian Abrahams | RBC Capital | Raises | Sector Perform | $72.00 | $67.00 |
| Jay Olson | Oppenheimer | Raises | Outperform | $82.00 | $81.00 |
| Jessica Fye | JP Morgan | Raises | Neutral | $71.00 | $65.00 |
| Evan Seigerman | BMO Capital | Raises | Underperform | $52.00 | $48.00 |
| Tazeen Ahmad | B of A Securities | Raises | Buy | $90.00 | $68.00 |
| Jessica Fye | JP Morgan | Raises | Neutral | $65.00 | $61.00 |
| Derek Archila | Wells Fargo | Lowers | Equal-Weight | $62.00 | $63.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Incyte. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Incyte compared to the broader market.
- Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.
To gain a panoramic view of Incyte's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Incyte analyst ratings.
Discovering Incyte: A Closer Look
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
A Deep Dive into Incyte's Financials
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Incyte's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 23.81%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Incyte's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 9.36% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 3.45%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 2.2%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.01, Incyte adopts a prudent financial strategy, indicating a balanced approach to debt management.
How Are Analyst Ratings Determined?
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
